NASDAQ$SGHT
Sight Sciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported strong second-quarter growth driven by Surgical Glaucoma and Dry Eye segments.
Sight Sciences reported a significant increase in revenue for the second quarter of 2021, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company's gross margin also saw substantial improvement. They completed an IPO raising $253 million.
- Total revenue increased by 258% compared to the prior year period, reaching $12.5 million.
- Surgical Glaucoma sales increased by 263% compared to the prior year period, totaling $12.0 million.
- Dry Eye sales increased by 169% compared to the prior year period, reaching $0.5 million.
- Gross margin expanded to 82% compared to 40% in the prior year period.
Headline financials
Revenue & EPS history
Sight Sciences · Revenue · Quarterly
$12.5M
Revenue by segment
Sight Sciences · $12.5M total across 2 segments · Q2 2021
- Interventional Glaucoma$12M+264.7%96.0%
- Interventional Dry Eye$500K+168.8%4.0%
Forward guidance
Sight Sciences projects revenue for the full year 2021 to range from $46 million to $48 million, which represents 66% to 74% growth compared to the prior year period.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.0%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+60.9%
Q3 2022
Best reaction
-26.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | +22.6% | +2.5% | |
| Q4 2025 | -26.9% | -25.9% | -34.9% | |
| Q3 2025 | +16.0% | +54.4% | +61.0% | |
| Q1 2025 | +1.3% | +8.3% | +38.6% | |
| Q4 2024 | +2.9% | +15.3% | -5.0% | |
| Q3 2024 | -17.1% | -17.1% | -24.1% | |
| Q2 2024 | -18.9% | -29.4% | -13.0% | |
| Q1 2024 | +6.6% | +1.1% | +17.4% | |
| Q4 2023 | +6.8% | -4.4% | +21.4% | |
| Q3 2023 | +19.8% | +2.0% | +54.1% | |
| Q2 2023 | +11.0% | +4.1% | -16.0% | |
| Q1 2023 | -0.4% | +0.6% | -25.1% | |
| Q4 2022 | +4.9% | -2.3% | -5.8% | |
| Q3 2022 | +60.9% | +50.4% | +72.9% | |
| Q2 2022 | -3.9% | -16.1% | -26.2% | |
| Q1 2022 | +11.2% | +23.9% | +59.2% | |
| Q4 2021 | -10.1% | -6.1% | -45.5% | |
| Q3 2021 | -2.4% | -5.8% | -20.6% | |
| Q2 2021 | -4.7% | +0.1% | -15.9% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro